BIO is Now Accepting Company Presentations for 2022 BIO International Convention
Company Presentations are a great way to increase your visibility at the BIO International Convention, especially in BIO One-on-One Partnering and attracting more partners to meet. These 13-minute podium presentations allow you to tell your company’s story and advance your business development goals. Applications are accepted for review and approval through May 27 or when spots sell out.
OLDER NEWS THAT'S WORTH REPEATING
MichBio Welcomes New Preferred Vendor - EIN PresswireMichBio Welcomes New Preferred Vendor - EIN Presswire
Earlier this year, MichBio's collaboration with press release distribution service BusinessWire expired. Since that time, we have been looking for a replacement service to make sure that our members are able to share their news when it happens, with the right audiences. We have developed a partnership with EIN Presswire.
All MichBio members are entitled to a free press release to try out the service, then contracts and renewals are eligible for discounts based on their size and scope.
Who is EIN?
EIN Presswire - Everyone's Internet News Presswire™ - has quickly become a relied upon service for professional communicators and when organizations need to get their news in front of the media, stakeholders, and the public that goes online looking for news. And EIN Presswire's pricing is incredibly affordable - hundreds, if not thousands of dollars less than other services, and there are many reasons for that - first and foremost because EIN Presswire owns and maintains its own proprietary distribution technologies.
EIN Presswire is a market disruptor.
The electronic press release distribution industry is decades old. Many of the original brands still use antiquated technologies and distribution methods that no longer work effectively in reaching an organization's key targets. Despite that, their distribution fees are prohibitively expensive, forcing clients to question the value these services provide. EIN is becoming the new "normal" in news distribution.
BIO Releases New Podcast on the Effect of Price Controls on the Industry
They are not the household names, but the medications they are researching and developing could be the lifeline patients are waiting for. Today we explore how drug price controls—now making their way through Congress—could have unintended consequences for the small biotechs that are the engine of the drug development ecosystem. And even worse, for the patients who need them most.
New Jersey Bio Releases White Paper Addressing the Myths About the Prescription Drug Supply Chain
Prescription Drug Affordability Boards are flawed—and would harm innovation and access to new treatments. An excerpt from the paper:
"Legislators are rightfully concerned that their constituents have timely access to the latest, most effective therapies. BioNJ Members share that concern and are working to ensure that every Patient has meaningful access to critical prescription treatments. New Jersey’s biopharmaceutical sector works closely with our Patient communities to deliver affordable medicines to them.
At times, Patients can struggle to afford their medications due to a complicated drug supply chain that includes rebates, reimbursement, copays, and coinsurance. To address this issue, New Jersey policymakers have unfortunately proposed the establishment of a Prescription Drug Affordability Board. BioNJ believes that a Prescription Drug Affordability Board is the wrong way to address Patient out-of-pocket drug costs. Rather than taking a holistic, system-wide approach to finding a solution to consumer costs, the proposed Affordability Board focuses primarily on the biopharmaceutical sector which has proven to be the source of treatment discovery and innovation."
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
